Skip to main content

Blue Heron Gets New CEO; Genomic Health OKs ’07 Salaries for Brass; Proteopure Names Invitrogen Alumnus to Board; and Others

NEW YORK (GenomeWeb News) — Ambit Biosciences, a small-molecule kinase-development company, has appointed Kerry Kelly to the position of vice president and general counsel, the company said Tuesday. Kelly recently was associate general counsel for The Scripps Research Institute and before that she was head of corporate affairs for biotech company Sugen, which has since been acquired by Pfizer.

 
Sample-prep kit maker Proteopure has appointed Ted DeFrank to its board of directors, the company said today.
 
DeFrank is president of management consulting company Dalton Enterprises and formerly was president of Pierce Biotechnology, COO of Invitrogen and vice president of operations at Stratagene.  

 
Codon Devices has hired Leda Notchey as its new senior director of marketing; Mario Alfano as its new director of automation; and Tyler Aldredge, who joins the company’s manufacturing operations.
 
Notcheywas formerly a senior executive in the life sciences branch at PerkinElmer; Alfano comes to the company from the discovery group at Millenium; and Aldredge previously worked at the Broad Institute’s DNA sequencing lab as a director of production operations. 
 
Codon Devices, based in Cambridge, Mass., develops gene libraries, engineered cells for pharma research, vaccines, and agricultural products.

 
Gene synthesis company Blue Heron Biotechnology has named John Fess CEO, the company said this week. Fess takes over for John Mulligan, who has shifted into the dual role of chairman and chief scientific officer.

 
Biosimulation company Gene Network Sciences has named Thomas Neyarapally to be vice president of corporate strategy and intellectual property, the company said.
 
Neyarapally previously worked at intellectual property firm Frommer, Lawrence and Haug, and was an associate at Chadbourne & Parke.

 
Biologic and molecular imaging company Visen Medical has appointed Geoffrey Ginsburg to its scientific advisor board, the company said this week. Ginsburg is director of the Center for Genomic Medicine at Duke University’s Institute for Genomic Studies, and he also is a professor of medicine and pathology.
 
Ginsburg specializes in identifying and applying biomarkers toward developing therapies for clinical medicine. 

 
UK biopharma developer Cambridge Antibody Technology has promoted three new executives to vice president positions, the company said this week.
 
Gaynor Fryers has been named vice president of business development. He has served the company since 2004 as business development director. Before coming to CAT Fryer was group commercial director at Bespak and worked in various roles at Bio Products Laboratory.
 
Ian Anderson has been named vice president of discovery, respiratory, and inflammation. He came to CAT from Glaxo Wellcome (before it became GlaxoSmithKline), where he worked in pharmacology and neuroscience.
 
Andy Williams is the new vice president of program management in the company’s drug-discovery department. Williams has been with CAT since 1993 and has worked in drug discovery and tech development.

 
Genomic Health last past week said its board of directors has approved 2007 base salaries for the company’s top executives: CEO and Chairman Randy Scott will be paid $280,000; Chairman, President and COO Kimberly Popovits will be paid $340,000; CSO Joffre Baker will be paid $310,000; Chief Medical Officer Steven Shak will be paid $315,000; and Executive vice president and CFO Bradley Cole will be paid $286,000.

Archemix, a biopharmaceutical company that develops single-stranded nucleic acids said on Monday it has appointed James McArdle to the post of vice president of chemistry, manufacturing, and controls.
 
McArdle was most recently at Isis Pharmaceuticals, where he was vice president of quality assurance. He also worked at SmithKline Beecham Pharmaceuticals for 16 years.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.